{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=40", "query": { "intervention": "Branch II", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 4756, "total_pages": 476, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=39&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T09:29:10.251Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00243022", "title": "Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Cerebral Edema" ], "interventions": [ { "name": "Boswellia serrata extract", "type": "DRUG" }, { "name": "cyanocobalamin", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Ali Altunkaya", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2004-09", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00243022" }, { "nct_id": "NCT05648110", "title": "Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19, SARS-CoV-2" ], "interventions": [ { "name": "AZD5156 (Parent study Sentinel Safety Cohort)", "type": "BIOLOGICAL" }, { "name": "Placebo (Parent study Sentinel Safety Cohort)", "type": "BIOLOGICAL" }, { "name": "EVUSHELD™ (Parent study Main Cohort)", "type": "BIOLOGICAL" }, { "name": "AZD3152 (Parent study Main Cohort)", "type": "BIOLOGICAL" }, { "name": "Placebo (Parent study Main Cohort)", "type": "BIOLOGICAL" }, { "name": "AZD3152 (Sub-study)", "type": "BIOLOGICAL" }, { "name": "AZD7442 - EVUSHELD™ (Sub-study)", "type": "BIOLOGICAL" }, { "name": "AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "12 Years to 130 Years" }, "enrollment_count": 3882, "start_date": "2022-12-16", "completion_date": "2025-02-11", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 130, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05648110" }, { "nct_id": "NCT02875613", "title": "Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Assuntina Sacco, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2017-01", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 2, "location_summary": "La Jolla, California • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02875613" }, { "nct_id": "NCT06496659", "title": "Segmentectomy After Induction Therapy (SAINT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Segmentectomy" ], "interventions": [ { "name": "Segmentectomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 25, "start_date": "2024-08-02", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06496659" }, { "nct_id": "NCT01728779", "title": "Stereotactic Body Radiation With Nelfinavir for Oligometastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oligometastases" ], "interventions": [ { "name": "Nelfinavir", "type": "DRUG" }, { "name": "Stereotactic Body Radiation (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2014-01-08", "completion_date": "2020-12", "has_results": true, "last_update_posted_date": "2021-07-12", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01728779" }, { "nct_id": "NCT00516243", "title": "Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Stage I Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer" ], "interventions": [ { "name": "placebo", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "OTHER" }, { "name": "questionnaire administration", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "PROCEDURE" }, { "name": "defined green tea catechin extract", "type": "DRUG" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "21 Years to 65 Years · Female only" }, "enrollment_count": 40, "start_date": "2007-07", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2014-09-12", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 4, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516243" }, { "nct_id": "NCT01915589", "title": "Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Refametinib (BAY86-9766)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2013-09-16", "completion_date": "2014-10-08", "has_results": false, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 5, "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 2 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01915589" }, { "nct_id": "NCT00709618", "title": "Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Lapatinib, Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 44, "start_date": "2008-06", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-07-14", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 22, "location_summary": "Muscle Shoals, Alabama • Tucson, Arizona • Sacramento, California + 19 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00709618" }, { "nct_id": "NCT00005097", "title": "Green Tea Extract in Treating Patients With Actinic Keratosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-melanomatous Skin Cancer" ], "interventions": [ { "name": "Polyphenon E and Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Frank Meyskens", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "1999-08", "completion_date": "2002-08", "has_results": false, "last_update_posted_date": "2018-04-05", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005097" }, { "nct_id": "NCT06172296", "title": "Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ganglioneuroblastoma, Nodular", "Neuroblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "FDG-Positron Emission Tomography and Computed Tomography Scan", "type": "PROCEDURE" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Tumor Resection", "type": "PROCEDURE" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 478, "start_date": "2024-04-19", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-22T09:29:10.251Z", "location_count": 158, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06172296" } ] }